^
Association details:
| Biomarker: | EGFR L858R + IDH1 R132C |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
P86.21 - Activating IDH Mutation as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC
Published date:
01/12/2021
Excerpt:
Patient 3 was firstly detected with EGFR_L858R (no IDH mutation) and treated with gefitinib. After acquiring gefitinib resistance, the patient was further treated with osimertinib. However, IDH1_R132C mutation appeared after osimertinib resistance, and then died in 2 months...Activating IDH mutations have been associated with short PFS and short OS.
